Company Overview and News

 
Pat Noland Appointed President Of Boston Heart Diagnostics

2017-05-25 devicespace
Noland brings a wealth of leadership experience in laboratory sciences to Boston Heart Diagnostics, a leader in personalized cardiovascular diagnostics and lifestyle services.
Upvote Downvote

 
Genetic Signatures launches novel infection detection kit

2017-04-03 proactiveinvestors.com.au
Molecular diagnostics company Genetic Signatures (ASX:GSS) has achieved a major breakthrough by launching the EasyScreen™ sexually transmitted infection (STI) detection kit.
Upvote Downvote

 
Top 300 Manufacturers of In-Vitro Diagnostics Products - Research and Markets

2017-02-14 prnewswire
Research and Markets has announced the addition of the "The Top 300 Manufacturers of In-Vitro Diagnostics Products Worldwide" report to their offering.
Upvote Downvote

 
Worldwide Top 600 In-Vitro Diagnostics Companies 2017 - Research and Markets

2017-02-03 prnewswire
Research and Markets has announced the addition of the "The Top 600 In-Vitro Diagnostics Companies Worldwide" report to their offering.
Upvote Downvote

 
Top 200 Molecular Diagnostics Companies 2017 - Research and Markets

2017-01-17 prnewswire
Research and Markets has announced the addition of the "The Top 200 Molecular Diagnostics Companies Worldwide" report to their offering.
Upvote Downvote

 
The Top 500 IVD Companies Worldwide

2016-11-24 prnewswire
- Diachel SA is the leading independent in-vitro diagnostics distributor in Greece, offering complete laboratory solutions, from sales to after-sales support and service.
Upvote Downvote

 
Genetic Signatures Ltd to undertake book-build

2016-08-30 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Upvote Downvote

 
Genetic Signatures Ltd continues expansion of disease diagnostic testing kit device in U.S.

2016-06-19 proactiveinvestors.com.au
Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.
Upvote Downvote

 
 
Appendix 3B

2016-04-14 asx.com.au
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

2018-04-25 - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...